NewsBenzingaReported Sunday, Genentech’s Divarasib Lowers Death Risk 44% In Phase III Krascendo 1 With Fewer TRAE Discontinuations (4.8% Versus 11.7%) Than Sotorasib Or Adagrasib In Previously Treated KRAS G12C NSCLC Reported Sunday, Genentech’s Divarasib Lowers Death Risk 44% In Phase III Krascendo 1 With Fewer TRAE Discontinuations (4.8% Versus 11.7%) Than Sotorasib Or Adagrasib In Previously Treated KRAS G12C NSCLC Benzinga 2026.10.26 07:28 (GMT+0) Open on Benzinga Other news Freedom Broker Maintains Buy on XPeng, Lowers Price Target to $20 Plug Power Shares Slide Toward 52-Week Low Despite New 280-MW Texas Deal Nvidia Vs. Anthropic: Can the AI IPO Challenge Nvidia’s Dominance Across ETFs? Freedom Broker Maintains Buy on Allot, Lowers Price Target to $12.7 Freedom Broker Maintains Hold on Skydance, Lowers Price Target to $8.5 Freedom Broker Upgrades M-Tron Industries to Buy, Lowers Price Target to $84